21 clinical trials found.
-
A Phase 1/2 Open-label Study Investigating the Safety Tolerability and Efficacy of ASP7517 in subjects with Relapsed/Refractory Acute Myeloid Leukemia (AML) and Relapsed/Refractory Higher Risk Myelodysplastic Syndrome (MDS)
The purpose of the study is to evaluate the safety and tolerability of intravenous infusion of ASP7517 (human embryonic kidney cell transfected with encoding target ...Phase
-
Single-arm open label phase II study of MBG453 (sabatolimab) added to FDA approved Hypomethylating agents of investigator s choice (IV/SC/Oral) for patients with intermediate high or very high risk myelodysplastic syndrome (MDS) as per IPSS-R criteria (US multi-center) (STIMULUS MDS-US)
The purpose of the study is to describe and evaluate safety and efficacy of MBG453 (sabatolimab) in combination with FDA approved Hypomethylating agents (HMA). We ...Phase
-
A Phase 3 Randomized Multicenter Double-Blind Placebo-Controlled Efficacy and Safety Study of Birtamimab Plus Standard of Care vs. Placebo Plus Standard of Care in Mayo Stage IV Subjects with Light Chain (AL) Amyloidosis
The purpose of the study is to evaluate the efficacy of birtamimab plus standard of care compared to placebo plus standard of care in Mayo ...Phase
-
A First in Human Study of theMenin-KMT2A (MLL1)Inhibitor JNJ-75276617 in Participants with Acute Leukemia
The primary objectives of this study are to determine the recommended phase 2 dose(s) (RP2Ds) of JNJ-75276617, as well as the safety and tolerability ...Phase
-
A Phase 1 Open-label Preliminary Pharmacokinetics (PK) and Safety Study of CLN-049 (An fms-like tyrosine kinase 3 [FLT3] x cluster of differentiation 3 [CD3] bispecific T cell engager) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)
The purpose of the study is to determine the safety and tolerability of intravenous (IV) administered CLN-049. CLN-049 is a novel BITE therapy that target ...Phase
-
A Multi-center Open-label Single-arm Phase 2/3 Trial Evaluating the Safety and Pharmacokinetics of Calaspargase Pegol for Treatment of Adults Aged 22 To >65 Years with Newly-diagnosed Philadelphia-negative ALL
The purpose of the study is to optimize the dosage of calaspargase pegol in newly-diagnosed Philadelphia-negative acute lymphoblastic leukemia (ALL) patients based on age. We ...Phase
-
A Phase IIa Open-label Clinical Trial to Evaluate the Safety Pharmacokinetics Pharmacodynamics and Efficacy of BP1001 (a Liposomal Grb2 Antisense Oligonucleotide) in Combination with Venetoclax plus Decitabine in Patients with Acute Myeloid Leukemia (AML) Who Are Ineligible for Intensive Induction Therapy
The first purpose of this study is to learn if combining the study drug BP1001 with the standard-of-care drugs Venetoclax and decitabine in first line ...Phase
-
AALL1631: International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Ph+ ALL Testing Imatinib in Combination with Two Different Cytotoxic Chemotherapy Backbones
The purpose of the study is to determine how well imatinib mesylate and combination chemotherapy work in treating patients with newly diagnosed Philadelphia chromosome positive ...Phase
-
A Phase 1 Open-label Multicenter Study Evaluating the Safety and Pharmacokinetics of Escalating Doses of IGM-2323 in Subjects with Relapsed/Refractory Non-Hodgkin Lymphomas
The purpose of the study is to evaluate how your body tolerates IGM-2323, the safety of IGM-2323, and how IGM-2323 is taken up by your ...Phase
-
AALL1821: A Phase 2 Study of Blinatumomab (NSC# 765986 IND# 125462) in Combination with Nivolumab (NSC# 748726 IND# 125462) a Checkpoint Inhibitor of PD-1 in B-ALL Patients Aged >/=1 to
The purpose of the study is to investigates how well nivolumab when given together with blinatumomab work compared to blinatumomab alone in treating patients with ...Phase
